Insights

Why the BARD1 (ASX:BD1) share price is climbing 6% today

The BARD1 Life Sciences Ltd (ASX: BD1) share price is climbing today following a favourable outcome for the company’s hTERT test.
The post Why the BARD1 (ASX:BD1) share price is climbing 6% today appeared first on The Motley Fool Australia. –

increase in asx medical software share price represented by doctor making excited hands up gesture

BARD1 Life Sciences Ltd (ASX: BD1) shares are climbing today following a favourable outcome for the company’s hTERT test. At the time of writing, the BARD1 share price has leapt 6.34% to $3.86. 

Let’s take a closer look at what the diagnostics company announced.

What’s pushing the BARD1 share price higher?

Investors have been driving up the BARD1 share price after the company provided a positive announcement before market open.

According to its release, BARD1’s hTERT test has been granted Class II In-Vitro Diagnostic (IVD) medical device registration from South Korea’s Ministry of Food and Drug Safety (MFDS).

The pleasing result will now see the company’s hTERT product distributed across South Korea through Mirax Corporation (Mirax). Previously in late 2018, BARD1 entered an exclusive distribution agreement with Mirax for the hTERT test.

Under the initial terms of the deal, BARD1 received a purchase order from Mirax within two days of receiving IVD registration. The first lot of hTERT products is expected to generate revenue of $80,000 for BARD1.

Addressable market opportunity

The South Korean medical device market is considered to be a massive opportunity for BARD1. In 2018, the country’s medical device market was ranked as the ninth-largest in the world and valued at more than US$6.8 billion.

Urological cancer, including bladder cancer, is seen as an increasingly significant health problem in South Korea. A 2011 published report stated that urological cancer accounted for 8% of all known cancers in the country.

What did management say?

BARD1 CEO Dr Leearne Hinch hailed the company’s progress, saying:

Securing Korean registration and our first order from Mirax is the culmination of the BARD1 team’s dedication and effort to expanding the geographical footprint for hTERT in Asia. We are excited to be entering the Korean market and are looking forward to working with the Mirax team to build a strong franchise for hTERT in this key Asian healthcare market.

Mirax CEO Sang-Ju Bae continued on to add:

Mirax believes there is a significant opportunity for hTERT to become a key product in the bladder cancer diagnostic market in Korea. We are confident that the Mirax / BARD1 partnership can position hTERT as a valuable tool for cytologists, pathologists and urologists in the fight against bladder cancer.

Foolish takeaway

The BARD1 share price changed little over the course of 2020, however, in 2021, it has gained more than 460% year to date.

Where to invest $1,000 right now

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes are the five best ASX stocks for investors to buy right now. These stocks are trading at dirt-cheap prices and Scott thinks they are great buys right now.

See The 5 Stocks

*Returns as of February 15th 2021

More reading

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

The post Why the BARD1 (ASX:BD1) share price is climbing 6% today appeared first on The Motley Fool Australia.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;


To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.


An active and funded account with a positive trading balance is required to continue to have access to the tools;


Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;


Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android App - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US Trades. Click Here!